Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

Biohaven Pharma (BHVN) Tops Q3 EPS by 49c; Reports Cash and Cash Equivalents of $523.9M

November 9, 2021 7:47 AM EST

Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.91), $0.49 better than the analyst estimate of ($2.40). Revenue for the quarter came in at $135.7 million versus the consensus estimate of $128.4 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

... More